ArticleJournal of blood medicine2021

Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).

Claudia Djambas Khayat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.